NEW DELHI - India's fifth largest generic drug firm Lupin wants to buy other drug formulation companies in the U.S., Latin America, Southeast Asia and the Middle East this year to expand its presence overseas its chairman said after announcing a sharp, but expected, drop in earnings for the fourth quarter ended March 31
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.
